Document Detail


Olmesartan improves left ventricular function in pressure-overload hypertrophied rat heart by blocking angiotensin II receptor with synergic effects of upregulation of angiotensin converting enzyme 2.
MedLine Citation:
PMID:  19171689     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
It is not clear how the blocking effect of angiotensin II receptors by olmesartan affects the functional recovery of pressure-overload hypertrophied heart. Hypertrophied heart was created by abdominal aortic banding above the celiac artery in Wistar rats at the age of eight weeks. Hypertrophied heart was excised and studied at 10 and 16 weeks after the operation (HT groups). For the last four weeks before the experiment, olmesartan (0.2 mg/kg per day) was administered subcutaneously by osmotic minipumps (Olm groups). Left ventricular function was measured by Langendorff perfusion. The levels of mRNA for angiotensin-converting enzyme (ACE), ACE2 and extracellular signal-regulated kinases (ERKs) in myocardium were analyzed by RT-PCR. Left ventricular systolic (+dP/dt(max), left ventricular systolic pressure) and diastolic functions (-dP/dt(max), tau) were impaired in HT groups, while in Olm groups they were significantly improved. The left ventricle to body weight (LV/BW) ratio increased significantly in HT groups, but in Olm groups the LV/BW ratio decreased significantly in comparison with HT groups. The ACE2 mRNA level was significantly higher in Olm groups as compared with HT groups. Plasma angiotensin II and the ERK mRNA level in HT groups increased significantly, but decreased in Olm groups in comparison with HT groups significantly. Olmesartan improved left ventricular function and hypertrophy through the increase of the ACE2 mRNA and decrease of both angiotensin II and ERK mRNA in pressure-overload rat heart.
Authors:
Kaiqiang Ji; Masahito Minakawa; Kozo Fukui; Yasuyuki Suzuki; Ikuo Fukuda
Related Documents :
10526909 - The impact of different echocardiographic diagnostic criteria on the prevalence of left...
19429469 - Long-term treatment with supraphysiological doses of nandrolone decanoate reduces the s...
12502909 - Cardiovascular physiology-changes with aging.
24805959 - Plasmin in urine from patients with type 2 diabetes and treatment-resistant hypertensio...
16567599 - Relationship between accurate auscultation of a clinically useful third heart sound and...
884789 - Efficacy of ambulatory systemic vasodilator therapy with oral prazosin in chronic refra...
3277589 - Pulmonary microvascular changes following fluid resuscitation in an ovine model of endo...
110289 - Effects of 4-dimethylaminophenol and co2edta on circulation, respiration, and blood hom...
23089499 - Advances in therapy for acute lung injury.
Publication Detail:
Type:  Comparative Study; Journal Article     Date:  2009-01-26
Journal Detail:
Title:  Therapeutic advances in cardiovascular disease     Volume:  3     ISSN:  1753-9447     ISO Abbreviation:  -     Publication Date:  2009 Apr 
Date Detail:
Created Date:  2009-03-20     Completed Date:  2009-05-28     Revised Date:  2009-11-19    
Medline Journal Info:
Nlm Unique ID:  101316343     Medline TA:  Ther Adv Cardiovasc Dis     Country:  England    
Other Details:
Languages:  eng     Pagination:  103-11     Citation Subset:  IM    
Affiliation:
Department of Thoracic and Cardiovascular Surgery, Hirosaki University School of Medicine, Hirosaki, Japan. ikuofuku@cc.hirosaki-u.ac.jp
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Angiotensin II Type 1 Receptor Blockers / administration & dosage*
Animals
Cardiomegaly / drug therapy*
Disease Models, Animal
Drug Synergism
Extracellular Signal-Regulated MAP Kinases / drug effects
Heart / drug effects*
Humans
Imidazoles / administration & dosage*
Male
Peptidyl-Dipeptidase A / drug effects,  metabolism
RNA, Messenger / drug effects
Rats
Rats, Wistar
Tetrazoles / administration & dosage*
Up-Regulation / drug effects
Ventricular Function, Left / drug effects*
Chemical
Reg. No./Substance:
0/Angiotensin II Type 1 Receptor Blockers; 0/Imidazoles; 0/RNA, Messenger; 0/Tetrazoles; 0/olmesartan; EC 2.7.11.24/Extracellular Signal-Regulated MAP Kinases; EC 3.4.15.1/Peptidyl-Dipeptidase A; EC 3.4.17.-/angiotensin converting enzyme 2

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Unilateral multicystic dysplastic kidney: a meta-analysis of observational studies on the incidence,...
Next Document:  Hyperaldosteronism in pregnancy.